Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19

Shu, Ting; Ning, Wanshan; Wu, Di; Xu, Jiqian; Han, Qiang‐Qiang; Huang, Mingbin; Zou, Xiaojing; Yang, Qingyu; Yuan, Yang; Bie, Yuanyuan; Pan, Shangwen; Mu, Jian; Han, Yu; Yang, Xiaobo; Zhou, Hong; Li, Ruiting; Ren, Yujie; Chen, Xi; Yao, Shanglong; Qiu, Yang; Zhang, Ding Yu; Xue, Yu; Shang, You; Zhou, Xi

doi:10.1016/j.immuni.2020.10.008

Cited by 262 publications

(322 citation statements)

References 63 publications

(63 reference statements)

Supporting

Mentioning

273

Contrasting

Order By: Relevance

“…Several recent investigations have identified protein biomarkers and clinical parameters that classify COVID-19 patients according to disease severity [7][8][9][10][11][12][13][14][15] . To identify i) which of these markers and parameters correlate with each other by being attributed to a common biological or physiological response, and ii) which markers predict outcome, we longitudinally phenotyped 139 individuals admitted at Charité University Hospital, Berlin, Germany, between March 01, 2020 and June 30, 2020 due to PCR confirmed SARS-CoV-2 infection (Supp.…”

Section: Covariation Of Clinical Diagnostic Parameters and The Plasmamentioning

confidence: 99%

“…A number of biomarkers that classify COVID-19 severity have recently been described, based on clinical chemistry, enzyme activities, immunoprofiling, single cell sequencing, proteomics, and metabolomics [7][8][9][10][11][12][13][14][15] . These severity classifiers characterize COVID-19 pathology and host responses mainly in blood, serum, plasma or immune cells.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A time-resolved proteomic and diagnostic map characterizes COVID-19 disease progression and predicts outcome

Demichev¹,

Tober‐Lau²,

Nazarenko³

et al. 2020

Preprint

View full text Add to dashboard Cite

COVID-19 is highly variable in its clinical presentation, ranging from asymptomatic infection to severe organ damage and death. There is an urgent need for predictive markers that can guide clinical decision-making, inform about the effect of experimental therapies, and point to novel therapeutic targets. Here, we characterize the time-dependent progression of COVID-19 through different stages of the disease, by measuring 86 accredited diagnostic parameters and plasma proteomes at 687 sampling points, in a cohort of 139 patients during hospitalization. We report that the time-resolved patient molecular phenotypes reflect an initial spike in the systemic inflammatory response, which is gradually alleviated and followed by a protein signature indicative of tissue repair, metabolic reconstitution and immunomodulation. Further, we show that the early host response is predictive for the disease trajectory and gives rise to proteomic and diagnostic marker signatures that classify the need for supplemental oxygen therapy and mechanical ventilation, and that predict the time to recovery of mildly ill patients. In severely ill patients, the molecular phenotype of the early host response predicts survival, in two independent cohorts and weeks before outcome. We also identify age-specific molecular response to COVID-19, which involves increased inflammation and lipoprotein dysregulation in older patients. Our study provides a deep and time resolved molecular characterization of COVID-19 disease progression, and reports biomarkers for risk-adapted treatment strategies and molecular disease monitoring. Our study demonstrates accurate prognosis of COVID-19 outcome from proteomic signatures recorded weeks earlier.

show abstract

Section: Covariation Of Clinical Diagnostic Parameters and The Plasmamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A time-resolved proteomic and diagnostic map characterizes COVID-19 disease progression and predicts outcome

Demichev¹,

Tober‐Lau²,

Nazarenko³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Host proteome analysis using blood has been instrumental in gauging the response of the host as well as identifying classifiers of severity that will be clinically useful. 61 , 108 …”

Section: Resultsmentioning

confidence: 99%

Role of Multiomics Data to Understand Host–Pathogen Interactions in COVID-19 Pathogenesis

et al. 2021

View full text Add to dashboard Cite

Human infectious diseases are contributed equally by the host immune system’s efficiency and any pathogens’ infectivity. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the coronavirus strain causing the respiratory pandemic coronavirus disease 2019 (COVID-19). To understand the pathobiology of SARS-CoV-2, one needs to unravel the intricacies of host immune response to the virus, the viral pathogen’s mode of transmission, and alterations in specific biological pathways in the host allowing viral survival. This review critically analyzes recent research using high-throughput “omics” technologies (including proteomics and metabolomics) on various biospecimens that allow an increased understanding of the pathobiology of SARS-CoV-2 in humans. The altered biomolecule profile facilitates an understanding of altered biological pathways. Further, we have performed a meta-analysis of significantly altered biomolecular profiles in COVID-19 patients using bioinformatics tools. Our analysis deciphered alterations in the immune response, fatty acid, and amino acid metabolism and other pathways that cumulatively result in COVID-19 disease, including symptoms such as hyperglycemic and hypoxic sequelae.

show abstract

“…For the 46 protein biomarkers described by Shu et al [1], 34 were available for measurement in the Somalogic platform: 4 of 18 were found to differ in PCOS for platelet…”

Section: To the Editormentioning

confidence: 99%

Biomarkers of COVID-19 severity may not serve patients with polycystic ovary syndrome

et al. 2021

View full text Add to dashboard Cite

Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19

Cited by 262 publications

References 63 publications

A time-resolved proteomic and diagnostic map characterizes COVID-19 disease progression and predicts outcome

A time-resolved proteomic and diagnostic map characterizes COVID-19 disease progression and predicts outcome

Role of Multiomics Data to Understand Host–Pathogen Interactions in COVID-19 Pathogenesis

Biomarkers of COVID-19 severity may not serve patients with polycystic ovary syndrome

Contact Info

Product

Resources

About